Revenue
Margin
Demand
Guidance
Tone
Dr. Agarwal's Health Care Limited - Q1 FY27 Earnings Call Summary Tuesday, August 4, 2026 5:30 PM IST
Event Participants
Executives (5)
Aashna Dharia, Dr. Adil Agarwal, Dr. Ashar Agarwal, Rahul Agarwal, Yashwanth Venkat
Analysts (4)
Maulik Patel, Nikhil Mathur, Parag Salarkar, Tushar Manudhane
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from operations | ₹614 crores | +26% YoY (+8.8% QoQ — strongest sequential growth on record); vs ₹487 crores in Q1 FY26 |
| Total income | ₹620 crores | +24% YoY |
| India revenue | ₹552 crores | +25.3% YoY; near-equal volume ( |
| Total surgeries | ~91,000 | +15.5% YoY; cataract ~74% of total (+16.5% YoY), other surgeries blended +13.3% |
| SSSG (pre-FY23 facilities) | 16.3% | ₹465 crores revenue, 75.9% of group revenue; volume 8% + value 8% (OPD growth 6%, in-house conversion 2%) |
| Ind-AS EBITDA | ₹177 crores | +25.2% YoY; margin 28.5% (+30 bps YoY) |
| PAT margin | 8.9% | +127 bps YoY despite rising greenfield losses |
| Greenfield losses | ~₹20 crores | At center EBITDA level; includes FY26 and FY27 launches plus pre-operating losses |
| High-end cataract mix | 29.3% | Of 67,000 total cataract surgeries; Femto-cataract 1,558 procedures (+33.4% YoY); SMILE +36.2% YoY |
| Retina surgeries | 3,861 | +30% YoY; cornea transplants 285 (highest ever quarter) |
| Avg realization per cataract | ~₹42,000 | Up from ₹28,000–30,000 four years ago; premiumization ~7.5% + price hike ~0.5% in Q1 |
| Payor mix | Cash 63.6% / Insurance 27.7% / Govt 8.6% | Insurance + TPA and government schemes increasingly contributing |
| Revenue mix | Surgeries 66% / Diagnostics 12% / Optical & pharmacy 22% | Surgical services remain primary driver |
| Finance cost | ~₹23.5 crores | Down from ₹24.7 crores YoY; interest on deferred acquisition payable fell to ₹3.6 crores from ₹6.8 crores; lease liability interest ~₹18 crores |
| Facilities | 285 (India) | +18 greenfield in Q1 (16 surgical — record); 165 cities, 14 states, 5 UTs; 31% Tier 1, 63% other, 6% international |
| Doctors | 1,057 | +23% YoY; ~100 added in last 4 months; overall attrition 16–17%, senior doctor attrition 2–3% only |
| Patients served | 8.8 lakh+ | ~12,000 patients/day across facilities |
Geographic & Segment Commentary
- Southern Region (63% of revenue): Delivered ₹387 crores, +22.8% YoY. 189 facilities (7 added). Only 65% of surgical facilities are fully mature, leaving significant ramp-up headroom. Growth driven by expansion beyond cataract into retina/cornea specialties, sharper digital marketing, and strengthened corporate relations engine.
- Western Region (15% of revenue): Delivered ₹91 crores, +24% YoY. 52 facilities including 5 new greenfield launches (Thane, Ulhasnagar, Moshi, Wagholi, Ahilya Nagar). Mumbai remains a key expansion focus; Gujarat leadership change already yielding stronger patient traction.
- Northern Region (9% of revenue): Delivered ₹57 crores, +50.5% YoY — fastest-growing region. 30 facilities (6 added). Punjab and J&K recovered from Operation Sindoor and floods impact. Delhi-NCR now has 8 facilities (Faridabad, Shahdara, Ghaziabad added this quarter), with 3–5 more planned.
- Eastern Region: Delivered ₹16 crores, +21% YoY. 14 facilities. New Kolkata leadership team focused on clinical excellence and business development.
Company-Specific & Strategic Commentary
- Greenfield Expansion Engine: 16 surgical facilities launched in Q1 — a record for any single quarter, nearly half of FY26's full-year surgical additions. Since FY23, 166 new greenfield facilities added (10 in FY23 accelerated to 18 in Q1 FY27 alone). 30+ signed LOIs in pipeline.
- Clinical Innovation — Pinhole Pupilloplasty (PPP): Developed by Chairman Dr. Amar Agarwal; offers donor-free alternative to corneal transplants. 500+ procedures performed last fiscal year with ~94% of patients showing significant visual acuity improvement. Global academic recognition with peer-reviewed publications and live surgical demonstrations.
- Premium Technology Adoption: Femto-cataract robotic surgeries grew 33.4% YoY; SMILE refractive procedures +36.2% YoY; retina surgeries crossed 3,861 (+30% YoY). Management compares PPP's potential to coronary stents transforming cardiology.
- Delhi-NCR Hub-and-Spoke Build-out: Eight facilities operational after 1+ year of entry; 3–5 more planned, deepening presence across micromarkets.
- Merger: Expected to close around mid-November; final items being closed.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Facility additions FY27 | 60 total (40 surgical) | Q1 delivered 18 (16 surgical); Q2 guided at 12; H2 at 30; 30+ signed LOIs provide strong pipeline confidence |
| SSSG — mature facilities | 12–13% sustainable | Management aspiration; 16.3% delivered in Q1 FY27 across pre-FY23 cohort |
| Merger completion | Mid-November | Final closing items in progress |
| Same-store growth drivers | Continued premiumization + volume | Realization per cataract (~₹42,000) expected to keep rising with Femto adoption, insurance penetration, and patient affordability |
Risks & Constraints
| Risk | Context |
|---|---|
| Greenfield ramp-up losses | ~₹20 crores at center EBITDA level in Q1, including pre-operating losses; rising as 23 new surgical facilities were launched in the last 6 months. Management expects these to taper as facilities mature over ~3 years. |
| Rapid expansion execution | 60 facility additions planned for FY27; execution depends on site compliance, property availability, and doctor onboarding. Management is actively working to improve launch pace but notes compliance constraints. |
| Doctor attrition and talent | Overall doctor attrition at 16–17% (includes junior doctors and students); senior doctor attrition only 2–3%. ~100 doctors added in last 4 months; productivity of new joiners still ramping up. |
| New market maturity lag | Delhi-NCR and other new geographies are 3+ years from achieving South-level maturity; utilization build-out will take time. |
| Technology cost intensity | Femto-cataract adds ~₹35,000 per procedure revenue vs ~₹10,500–11,000 click fee — rupee gross margins improve, but mix shift could pressure near-term margins if adoption accelerates faster than anticipated. |
Q&A Highlights
Premiumization vs. Price Hike Split
- Question: How much of the revenue growth is value (case mix + price) vs. volume? (Maulik Patel — 360 ONE Capital)
- Answer: Premiumization contributed ~7.5% and price hike ~0.5%, totaling ~8% on a like-to-like basis; balance was volume growth. (Rahul Agarwal, COO)
Greenfield Loss Magnitude
- Question: What is the quantum of losses from recently opened facilities? (Maulik Patel)
- Answer: ~₹20 crores at center EBITDA level for the quarter, including both FY26 and FY27 launched centers and pre-operating losses. (Yashwanth Venkat, CFO)
Interest Cost Decomposition
- Question: Can you split interest cost between lease liability and deferred acquisition liability? (Nikhil Mathur — SIMPL)
- Answer: ~₹24 crores paid toward acquisition liability in Q1; interest on lease liability ~₹18 crores; interest on deferred acquisition payable down to ₹3.6 crores from ₹6.8 crores YoY. (Yashwanth Venkat, CFO)
SSSG Volume vs. Value Break-up
- Question: For mature facilities, what is the footfall growth within the 16.3% SSSG? (Nikhil Mathur)
- Answer: For pre-FY23 facilities, volume 8% and value 8%; OPD growth contributed 6% of value with 2% from in-house conversion. Newer cohorts see higher volume contribution as they ramp. (Rahul Agarwal, COO)
North Region Growth Drivers
- Question: Is North's strong growth purely Delhi-NCR driven, or visible in smaller markets too? (Nikhil Mathur)
- Answer: Delhi-NCR is a new entry (1 to 8 branches in a year) and the largest driver; Punjab also benefited from Operation Sindoor base effect. All North branches showing positive trends, but Delhi centers are years away from South-level maturity. (Rahul Agarwal, COO)
Doctor Additions and Attrition
- Question: Are the 23% YoY doctor additions for new facilities or also existing ones? (Tushar Manudhane — Motilal Oswal)
- Answer: Most additions are for new centers, especially Maharashtra and Delhi-NCR; 100 doctors added in last 4 months. Overall attrition 16–17%, but senior doctor attrition is only 2–3%. (Adil Agarwal, CEO)
Realization Growth Sustainability
- Question: Can average realization growth of ~10% sustain over next 12–15 months, or will it plateau? (Tushar Manudhane)
- Answer: Average realization per cataract has risen from ₹28,000–30,000 to ~₹42,000 over 4 years, driven by insurance, disposable income, and better lens adoption. Femto-cataract adds ~₹35,000 per procedure with only ~₹10,500–11,000 click fee cost, boosting rupee gross margin. Directionally, realization growth should continue. (Rahul Agarwal, COO; Yashwanth Venkat, CFO)
Facility Launch Pace Acceleration
- Question: Can the launch pace be increased further given strong cash flow? (Tushar Manudhane)
- Answer: Working actively to improve launch pace; Q1 set a benchmark. Compliance-compliant property availability is a constraint, but pipeline of 30+ LOIs supports the 60-facility FY27 plan. (Adil Agarwal, CEO)
South Region SSSG Sustainability
- Question: Will South's 23% regional growth and mature facility SSSG sustain at elevated levels? (Maulik Patel)
- Answer: South SSSG is in line with the ~16.5% cohort growth; management views 12–13% sustainable SSSG as phenomenal and is appreciative of the 16.3% delivered. (Adil Agarwal, CEO)
Merger Timeline
- Question: When will the merger complete? (Parag Salarkar, individual investor)
- Answer: On track for mid-November; final items are being closed. (Adil Agarwal, CEO)
Key Takeaway
Dr. Agarwal's recorded its strongest quarter in Q1 FY27, with revenue from operations of ₹614 crores (+26% YoY, +8.8% QoQ), Ind-AS EBITDA margins of 28.5% (+30 bps), and PAT margin expanding 127 bps to 8.9% despite ₹20 crores of greenfield losses. The company launched 18 facilities (16 surgical — a record), bringing the network to 285 facilities across 165 cities, and is guiding to 60 total facility additions for FY27 with 30+ signed LOIs. Mature facility SSSG of 16.3%, premiumization (~7.5%), and high-end procedure growth (Femto +33.4% YoY, retina +30% YoY) underpin the growth story, while the proprietary PPP innovation (94% visual acuity success in 500+ procedures) represents a potential global paradigm shift in corneal care. The North region's 50.5% YoY growth and Delhi-NCR build-out (8 facilities, 3–5 more planned) are key strategic pivots, with merger completion expected mid-November. Watch items include greenfield ramp-up losses, doctor onboarding at scale (1,057 doctors, 100 added in four months), and realization sustainability as premium mix and technology adoption (₹42,000 average realization per cataract) continue to rise.
Transcript incomplete — the following sections were not available: None. Full transcript covered management discussion, all financial disclosures (revenue, EBITDA, PAT, segment performance, SSSG, payor mix), geographic breakdown, strategic updates (greenfield expansion, PPP innovation, Delhi-NCR build-out), guidance (60 facilities FY27, merger mid-November), Q&A with 4 analysts, and concluding remarks.